BRD4 and Burkitt lymphoma: JQ1, iBET, and bromodomain inhibitors selectively bind to the domains of BRD4,78,79 which causes selective repression of the MYC oncogene in a wide range of tumors including multiple myeloma (MM), Burkitt’s lymphoma (BL), AML, and ALL60–63,80 (Table 2).